 So with that said, it's a real distinct pleasure to now introduce the next panel, which is the regulatory landscape in India. We had a great presentation last year where we heard about some of the reforms that were occurring in India. I think we have a really committed group of senior global biopharmaceutical leaders who want to see us ramp up our ability to drive access to patients in India. I couldn't imagine a better moderator and Muna, I'll hand it over to you. You can introduce yourself and the panel and please take it away. Thank you, Anthony. And we're delighted to kick off this next discussion by welcoming Dr. Mandeep Bandari, who's the joint secretary, ministry of health and the government of India. And I also would like to welcome the drugs controller general of India, Dr. Samani. And we're just delighted to have you both here for us for this discussion. India's determination to bolster the country's preparedness to address health care priorities is evident not only from the announcement of the self-reliant India package, but also from the steps being taken to drive the regulatory reforms and enhance the ease of doing business for our industry. Dr. Samani and Dr. Bandari will share their perspectives on these reforms, including the conduct of clinical trials in India and the efforts to ensure the high degree of safety and timeliness of access of treatments for patients. So Dr. Samani, perhaps we can start with you. At last year's conference, we heard a bit about the reforms underway designed to strengthen the clinical trials environment as well as address the pain points that are being experienced by the sponsors. Can you speak to the progress that has been made and what we can expect in the coming year? Thank you, Mona, for this wonderful opportunity. The most important thing, what the innovators and the sponsor wants at the great sense of partnership, transparency, predictability, and the timelines to be followed. And on all these fronts and easily understandable regulations which are digitally available so that they can interact online with the regulators and all these front, the regulations have been modified. The regulations have come in picture from March 2019 and thereafter, the pre-submission meeting, the timelines for the newly discovered drugs to give the clinical trial protocol approvals within 30 days and also fast track approval, pre-submission meeting and post-submission meeting. This has been very encouraging and we have done that. And at times when the drugs are or the therapeutic options are such that which will address the unmet need or serious life-threatening diseases and there is no probability of a difference in safety and efficacy parameters or in such cases, the waiver of local clinical trial is also enabled and many such drugs have been approved in India and sponsors and various innovators are finding it very useful. This waiver, online operation, pre-submission meeting, they are finding it quite useful. So these are some of the enabling environment which are taken from the regulatory perspective. Dr. Bandari, would you care to add your perspective as well around how you see the ecosystem continuing to shape up to support the early stage trials as well? I think Dr. Bandari could not join. He was finding some trouble joining with the link. Perhaps then we can continue and hopefully he will be able to call in. And so Dr. Sopani, we all have seen a significant amount of steps being taken by regulatory agencies around the world to enable the COVID-19 related trials as well as approve the therapeutics for emergency use authorization. Can you speak to the actions that you have authorized in India? The COVID has brought a definitive challenges. When it came, diagnostic options, therapeutic options were very limited. We never knew how this virus is. And on the 19th March, you will not believe that there was not a single kit which can detect this, neither antigen nor antibody or nor RTPCR. Thereafter, India has taken this task and indigenously developed more than 70 operators who are having the RTPCR antigen clear and various kinds of kits available in India. And 250 operators, more than 250 operators who are importer also. Most of them are from U.S. Also, they have been given approval with regards to and they are all on the emergency basis. We had to work day and night to see the performance evaluation and testing with regards to therapeutic options, therapeutic options. We were, you know, as many operators have come with the trial proposal starting from the gene therapy product to small molecules, to biologicals, vaccines, and also various kinds of other options. We have worked hand in hand with them. We have started special meetings and those special meetings were being held every day of the subject expert committees and the CDSCO over here was working to review all these trial applications and the emergency use authorization applications also. And in this regard, I would like to tell you, we never, because the response during pandemic is different than what is the response during the peacetime. The public, the doctors and the overall society is ready to accept the rapid response or sometimes accept, you know, more risk in comparison to what they can accept during the peacetime. So based on that and also based on the experience of various operators, various companies or various partners in the USA, we also depended on what has been approved in US. So one example I would give you, the Remdesivir. That was approved under emergency use authorization and the Gilead has given voluntary license to four or five manufacturers over here, six manufacturers and those manufacturers were audited, their products were tested, entire comparability were tested, their stability was ensured. And now today you will see there are five manufacturers manufacturing Remdesivir in India after due approval by the DCGA under the emergency use authorization. We have put some additional conditions also like having the informed consent and all that. Similarly, the drugs, which can also stop the cytokine storm, which is available in our country for a long time on the Etoilus map that has also undergone the clinical trial in India, randomized controlled clinical trial. And it was also given emergency use authorization for this added level indication. And thirdly, the Favipiravir. You wanted to say something? Please continue. The Favipiravir that this therapeutic option was also tried, a randomized controlled trial was conducted in India. And after getting the reasonable results, which are, that was also given the emergency use authorization. And now there are more than 170 products which are under trial. Of course, which includes various vaccines also. And of course, for that the emergency use authorization is not presently in the considerations. They are going through the phase two and the phase three trials in India. They have reached to that level. And we are quite sure that they will be coming soon. So thank you for that update. And I see that perhaps Dr. Bandari has been able to join us. Dr. Bandari, are you on? Yeah, very good evening. Sorry for getting things slightly wrong in terms of technology and all those things. But finally, I've been able to join. Thank you. And welcome. So just to pick up on the conversation that we were having, can you speak to the fact that the government of India has set up an expert committee to guide the financing distribution and the administration of the COVID-related vaccines? What role do you see the industry being able to play in partnership in this area? Well, first of all, thanks a lot for giving me this opportunity on behalf of the government of India. As Dr. Samani, who's a drug controller general of India, he would have briefed, we are very seriously looking at a lot of hand-holding and support for the COVID-related, both vaccines and the pharmaceuticals and other products for which the clinical trial rules which the government of India brought into place last year, it sets up a whole ecosystem for clinical trials in the country. We're looking big time for the players, for the industry to be coming to the country for doing the clinical trials for which we are more than eager to provide them with all kind of support. As such, the clinical trial rules and regulations, they provide a lot of support to the industry, to the new players, for the innovators, for the new launches of the drugs to come over to do the clinical trials here. And in terms of the systems, they availability of the time-bound disposal of the processes which enable the industry, as also in terms of the infrastructure, the hand-holding, which the drug controller and his team would do, that is something which we have built into our regulations. And I'm very sure that the industry would take note of this. And in these trying times, we have a lot of support from there. Thank you. And I think it is on that note of optimism and support in the sense of the partnership that I feel that we now need to conclude the panel discussion. It was a short one, but a terrific one. And I want to just take a moment to recognize the partnership that we have as an industry with the government of India to continue to deliver the innovations to the patients while that we serve. The country truly has the potential of becoming a leading destination for investment in R&D as well as in manufacturing with policies that are aligned to global standards. So thank you again to Dr. Bandari, to Dr. Samani for joining us for this timely discussion.